KAEL-GemVax Co., Ltd.
🇰🇷South Korea
Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer
Phase 3
- Conditions
- Inoperable Stage III Non-small Cell Lung Cancer
- Interventions
- Drug: normal saline
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Kael-GemVax Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT01579188
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
Phase 2
- Conditions
- Prostate Cancer
- Interventions
- Other: placeboBiological: BCG vaccineBiological: prostate cancer vaccine ONY-P1
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Kael-GemVax Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT00514072
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath